Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies

Lupus

Volumn 6, Issue 9, 1997, Pages 723-729

  George, J ^a   Afek, A ^a   Gilburd, B ^a   Levy, Y ^a   Blank, M ^a   Kopolovic, J ^a   Harats, D ^a   Shoenfeld, Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Atherosclerosis; Autoimmunity; Oxidized LDL

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; LIPID BLOOD LEVEL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 0030727283     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600908     Document Type: Article

References (31)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
2. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis:current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
3. Wick G et al Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33.
4. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. Immunol Res 1996; 155: 315-322.
5. Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol Today 1989, 10: 123-126.
6. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8: 1296-1303.
7. Shoenfeld Y, George J. Induction of autoimmunity: a role for the idiotypic network. Ann NY Acad Sci 1997; 815: 343-349.
8. Bakimer R et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-1563.
9. Blank M, Tincani A, Shoenfeld Y. Induction of experimental anti-phospholipid syndrome in naive mice with purified antiphoshphatidylserine antibodies. J Rheumatol 1994; 21: 100-104.
10. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342, 341-344.
11. Khamashta MA, Hughes GRV. Antiphospholipid syndrome. A common cause of thrombosis. Br Med J 1993; 307: 883-884.
12. Simantov R et al. Activation of cultured endothelial cells by antiphopholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
13. Del Papa N et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997; 3: 551-561.
14. La Tonqueze M et al. Role of β2-glycoprotein 1 in the antiphospholipid antibody binding to endothelial cells. Lupus 1995, 4: 179-186.
15. Hasunuma Y et al. Involvement of β2 glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573
16. Pierangeli SS, Harris EN. Induction of phospholipid binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993; 93: 269-272.
17. Pierangeli SS et al. Thrombogenic properties of murine anticardiolipin antibodies induced by β2-glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94: 1746-1751
18. Vaarala O et al. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein. Clin Exp Immunol 1996; 104: 269-274.
19. Horkko S et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996; 98: 815-825.
20. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
21. Ishibashi S et al. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus mediated gene delivery. J Clin Invest 1993; 92: 883-893
22. Xu Q et al. Induction of arteriosclerosis in normocholesterolemic mice rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-799.
23. George J et al. Oxidized low density lipoprotein (oxLDL) but not LDL aggravates the manifestations of antiphospholipid syndrome (APS). Clin Exp Immunol 1997; 108: 227-233.
24. Paigen B et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987; 68: 231-240.
25. Rubin EM et al. Inhibition of early atherogenesis in transgenic mice by human apoplipoprotein A-I. Nature 1991; 353: 265-267.
26. Qiao JH et al. Pathology of atheromatous lesions in inbred and genetically engineered mice: genetic determinations of arterial calcification. Arterioscler Thromb 1994; 14: 1480-1497.
27. Vaarala O et al. Anticardiolipin antibodies and the risk of myocardial infarction in a prospective cohort of middle aged men. Circulation 1995; 91: 23-27
28. The Antiphospholipid Antibodies and Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069-2073.
29. Matsuura E et al. Heterogeneity of anticardioloipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-3891.
30. Matsuura E et al. Anticardiolipin antibodies recognize β-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457.
31. Puurunen M et al. Antibody against oxidized LDL predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.